GtoPdb Ligand ID: 6881

Synonyms: Actemra® | R-1569 | RG-1569 | RHPM-1 | RoActemra®
tocilizumab is an approved drug (FDA (2010), EMA (2009))
Compound class: Antibody
Comment: Tocilizumab is an anti-IL-6 receptor mAb, with immunosuppressive action [6] that is approved for chronic autoimmune indications.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Qyuns Therapeutics have a potential tocilizumab biosimilar (QX003S) in Phase 1 evaluation for rheumatoid arthritis (trial registry number ChiCTR1900021808).

In early March 2020, China's National Health Commission issued guidance that allows use of tocilizumab to treat patients with serious COVID-19-induced lung damage. Tocilizumab is predicted to mitigate against the uncontrolled immune response that is triggered by SARS-CoV-2 infection in some patients and which leads to potentially life-threatening lung damage.
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: tocilizumab

Compound class Antibody
Approved drug? Yes (FDA (2010), EMA (2009))
International Nonproprietary Names
INN number INN
8394 tocilizumab
Actemra® | R-1569 | RG-1569 | RHPM-1 | RoActemra®
Database Links
Specialist databases
IMGT/mAb-DB 96
Other databases
GtoPdb PubChem SID 178103463
Immunopaedia Search tocilizumab
PubChem SID 178103463
Search PubMed clinical trials tocilizumab
Search PubMed titles tocilizumab
Search PubMed titles/abstracts tocilizumab
Wikipedia Tocilizumab